Citizens raises Exelixis stock price target to $65 on ESMO data
Citizens raised Exelixis (EXEL) price target to $65, citing strong data on cabozantinib. EXEL trades near 52-week high, up 58.5% YTD. Q2 earnings beat EPS estimates but missed on revenue. FDA extended zanzalintinib review. Citizens maintains Outperform, BMO initiates with Perform rating.
How this was made
The 30-second read
Why it matters
Analyst upgrade and higher price target provide a fresh catalyst beyond the earnings recap.
Market read
The new price target may drive short-term buying interest in EXEL.
What to watch
Potential patent cliff and modest revenue miss could limit upside.
Background
Exelixis reported Q2 earnings that beat EPS expectations but missed revenue forecasts, prompting mixed analyst commentary.
Ticker impact
Citizens raised its price target on Exelixis to $65 from $55 and maintained an Outperform rating, citing upcoming ESMO data and recent earnings beat.
likely upward pressure as investors price in higher target
The new target reflects fresh analyst optimism after Q2 earnings beat and upcoming trial data, which can attract buying.
Market effects
Positive sentiment may spill to other biotech firms with oncology pipelines.
U.S. biotech sector could see modest gains.
Limited to investors tracking oncology drug developments.
Counterpoint
The price target raise may be premature given pending FDA review extensions and competitive pressures.
Key entities
- AnalystCitizens
Raised price target to $65, maintained Outperform rating.
- AnalystBMO Capital
Initiated coverage with a $54 price target.
